Syntekabio (KOSDAQ: 226330), a leader in artificial intelligence-driven drug development, is set to make a significant impact at the upcoming BioTechX USA conference in Philadelphia, PA, from September 17-18, 2024. As the Title Sponsor of the event, Syntekabio will take center stage to demonstrate its advanced AI solutions that are revolutionizing the pharmaceutical industry.
The company’s participation at BioTechX USA comes at a crucial time when the integration of AI in drug discovery is gaining momentum. Syntekabio’s presence underscores the growing importance of AI technologies in accelerating research and development processes in the pharmaceutical sector.
Dr. Jongsun Jung, CEO of Syntekabio, expressed enthusiasm about the opportunity to showcase their technologies, stating, ‘We look forward to meeting with potential clients at BioTechX and discussing how our AI-driven technologies can improve and accelerate their R&D activities.’ This statement highlights the company’s commitment to fostering collaborations that could potentially lead to breakthroughs in drug discovery.
One of the key highlights of Syntekabio’s presentation will be their innovative ‘Develop Now, Pay Later’ offer. This unique business model allows clients to validate target proteins of interest without incurring upfront costs, potentially removing financial barriers to early-stage drug discovery. The company’s STB LaunchPad program, powered by its proprietary DeepMatcher® technology platform, aims to deliver hits, optimized leads, and IND-enabled candidates, with clients only paying upon the delivery of agreed-upon validated results.
Syntekabio’s participation at BioTechX USA will include a keynote presentation by Dr. Jonathan Witztum, CTO of Syntekabio USA, titled ‘Addressing Data Scarcity in Drug Discovery with Physics-based AI Models.’ This presentation promises to shed light on innovative approaches to overcoming one of the significant challenges in AI-driven drug discovery – the scarcity of relevant data.
Additionally, Dr. Jongsun Jung will deliver a presentation on ‘Flexible Molecular Docking for Neoantigen & Antibody Drug Prediction; Pre-Clinical Application,’ showcasing Syntekabio’s capabilities in biologics discovery. The company will also highlight its in silico biologics platforms, Neo-ARS™ and Ab-ARS™, which enable personalized or universal neoantigen cancer vaccine and novel antibody drug prediction, respectively.
Syntekabio’s AI technology accesses over 10 billion known compounds and 1,400 in vitro/in vivo compatible drug targets, covering over 70% of human diseases. This vast database is powered by the company’s AI Bio-Supercom Center, boasting an impressive infrastructure of 5,000 servers, 40,000 CPU cores, and 2,500 GPUs. These resources fuel Syntekabio’s algorithms and drive their comprehensive suite of advanced proprietary tools designed to accelerate the drug discovery and development process.
The implications of Syntekabio’s technologies extend beyond just faster drug discovery. By leveraging AI to identify potential hits, optimize small molecule leads, and predict antibodies and cancer neoantigens, the company is paving the way for more targeted and potentially more effective therapeutics. This could lead to significant advancements in personalized medicine and cancer treatment.
As the pharmaceutical industry continues to embrace AI technologies, Syntekabio’s presence at BioTechX USA represents a significant step forward in bridging the gap between traditional drug discovery methods and cutting-edge AI solutions. The company’s participation not only showcases its technological prowess but also highlights the potential for AI to transform the landscape of drug development, potentially leading to faster, more efficient, and more cost-effective ways of bringing new treatments to patients.
Attendees of BioTechX USA are encouraged to visit Syntekabio’s booth (#401) or schedule a meeting to learn
This news story relied on a press release distributed by News Direct. Blockchain Registration, Verification & Enhancement provided by NewsRamp™. The source URL for this press release is Syntekabio Showcases AI-Driven Drug Discovery Solutions at BioTechX USA.